A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.